Breaking News

Neurophth Secures $95M in Series C+ Financing for Clinical Trials

Funds will be directed towards advancing clinical trials, enhancing R&D capabilities, and expanding Neurophth’s pipeline.

Neurophth Therapeutics, Inc., a gene therapy company for ophthalmic diseases, reported the closing of nearly $95 million in Series C+ financing. The round was co-led by Yangtze River-CMB International Industry Fund, Wuhan Optical Valley Financial Holding Group, Wuhan Hi-Tech Holding Group, Hubei KTLC and Guangzhou Jinkong Fund. The raised funds will be directed towards advancing clinical trials for Neurophth’s core products, enhancing the firm’s R&D capabilities, and expanding it...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters